Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, Chiu H, McBride J, Johnson C, Xin Y et al (2016) Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-pd-l1 monoclonal antibody, an immune checkpoint inhibitor. MAbs 8(3):593–603
2. Fu W, Liu C, Dorff S, Liu Q, Yu J, and Charlab OR (2016) Clinical pharmacology and biopharmaceutics review for atelolizumab in locally advanced or metastatic urothelial carcinoma 761034Orig1s000. Center for Drug Evaluation Research
3. Stein A, Ramakrishna R (2017) Afir: A dimensionless potency metric for characterizing the activity of monoclonal antibodies. Pharmacomet Syst Pharmacol 6(4):258–266
4. Ahmed S, Ellis M, Li H, Pallucchini L, Stein AM (2019) Guiding dose selection of monoclonal antibodies using a new parameter (aftir) for characterizing ligand binding systems. J Pharmacokinet Pharmacodyn 46(3):287–304
5. DeWitt AE, Dong JY, Wiley HS, Lauffenburger DA (2001) Quantitative analysis of the egf receptor autocrine system reveals cryptic regulation of cell response by ligand capture. J Cell Sci 114(12):2301–2313
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献